Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. - Wikidata - wikimedia - TriplyDB

Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.

Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.

http://www.wikidata.org/entity/Q43202139

about

pH, healing rate, and symptom relief in patients with GERD.Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients.Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole Relation between gastric acid output, Helicobacter pylori, and gastric metaplasia in the duodenal bulb Influence of HRH2 promoter polymorphism on aberrant DNA methylation of DAPK and CDH1 in the gastric epithelium.Frequent non-response to histamine H2-receptor antagonists in cirrhotics.How to Review a Meta-analysis Sufotidine 600 mg bd virtually eliminates 24 hour intragastric acidity in duodenal ulcer subjects Progress with proton pump inhibition.Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit.Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.Systematic reviews: the good, the bad, and the ugly.Historical impact to drive research in peptic ulcer disease.Resistant duodenal ulcer: when, why and what to do?Acid suppression in healthy subjects following lansoprazole or pantoprazole.Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity.Review: eradication of Helicobacter pylori. Problems and recommendations.pH, healing rate and symptom relief in acid-related diseases.The history of acid inhibition.Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.Peptic ulcers can now be cured without operation.Effect of gastrectomy on G-cell density and functional activity in dogs.pH-feedback controlled infusions of ranitidine are no more effective than fixed-dose infusions in reducing gastric acidity and variability in antisecretory responses Inhibition of gastric secretion following single morning or twice daily oral administration of sufotidine to volunteers.Acid suppression.Do H2 receptor antagonists have to be given at night? A study of the antisecretory profile of SKF 94482, a new H2 receptor antagonist which has a profound effect on daytime acidity.Inhibition of nocturnal acidity.Effect of Wy-45,727 on 24 h intragastric acidity in twenty normal volunteers.Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.Interaction of liquid aluminium phosphate and aluminium hydroxide with the gastric acid profile. Influence of food components and timing of meals.Medical treatment of duodenal ulcer: acid inhibition or Helicobacter pylori eradication?Gastroprotective properties of Myristica malabarica against indometacin-induced stomach ulceration: a mechanistic exploration.Severe gastroesophageal reflux disease.Low-dose cimetidine in the acute treatment of duodenal ulcer. Comparison of a single nocturnal dose regimen with a twice daily regimen.

P2860

Q33898648-20825518-C672-4CC6-9722-6061B5D586E9 Q34391841-1CA5FB11-B6BB-4E7C-A2EC-789B8773C3F4 Q34409080-CD3842E3-64B5-4A8B-830C-6DDBA1FF3A2A Q34410052-D68B19AD-589E-4D20-9143-C7371CD27701 Q34528757-7773BC72-B4AA-4196-8E9D-5DB18F995F6C Q34532039-ACB44A9E-0E2E-4063-A987-B4D232693F33 Q34996708-8BF6CAEB-7D7B-4A80-BDFC-0D22FC6462A0 Q34998772-51C584EB-136A-45D8-8AA7-86FA891DE4D7 Q35242583-6153F337-A0CC-4BFE-BDCB-7169550E539C Q35250682-5C4F4D39-775D-48E5-AEC2-99F19B448816 Q35705841-034E416E-14E5-49E8-A78F-7950FAFB42C3 Q35861879-2E68B071-DD45-40BD-BA25-281DDEDFA360 Q37471456-DFB0A3D8-EFE2-4782-9FAC-3E3F62A21460 Q37957695-90A45E10-9CC2-4B8C-88D2-1BA648C7A6F2 Q39178749-4F677DB1-9B1B-4EFB-B30B-F45F0EC9A37C Q39409890-CDEDCAC9-8AFF-42B7-A584-8364B0E168E9 Q39440440-13DC1C33-BE80-4B03-97E4-4AD2173EFB0C Q39445984-3879DB7A-BC53-476D-942F-C3CE60E668FD Q39453816-8770BC4A-6BB5-4244-84F5-23B0FAC09011 Q39466756-6F8CAB62-7BB3-4838-AD71-ADE46212C410 Q40383604-0F8AAE8E-237A-4E78-AE86-ACFCED577F7C Q40422122-68DEB142-CA71-471C-98A9-A51AB418BCC3 Q40436639-B4CDB4C1-F531-4AD0-983E-E37E792A071F Q41812982-81605EF5-53E3-4F48-B4B3-8A17D1746A06 Q41866048-18B4D716-F934-495E-9EC6-CFFEAF5D1D86 Q42213021-10FA9826-4D99-4559-A7F3-0833A8A3353E Q43173159-2C571B5C-2C3B-40F6-A92F-FA25E3637C21 Q43188474-1A49DA57-8F8C-497D-8520-8A98628B2526 Q43219611-104496CE-711D-4C2C-8C39-A6E50CD29B97 Q43222332-BCCBB684-B5D7-48C8-B976-4CF65CFD5AB6 Q43742711-2DF8C284-6AFA-4FB4-9B2C-6D0772A5B906 Q43782306-64F0BEEE-B1D7-4014-9B63-DCE659DA080C Q43944835-645CEBDF-AFCD-43A1-873E-E3C640ECC66F Q44060114-41F8E7B6-C7DC-498F-BE7C-EB405D83417D Q44475184-FB740D60-322B-42B1-A541-B206AF3D667B Q46919786-6705425E-D9A7-4BCB-ACC3-9079F2C8F743 Q50050121-DAC42649-90CC-41E9-A4AA-5050755CC05B Q52469454-861BAF6C-5056-48D2-9966-C2B4C0FE8E44

P2860

Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.

http://www.wikidata.org/entity/Q43202139

description

1987 nî lūn-bûn

@nan

1987年の論文

@ja

1987年学术文章

@wuu

1987年学术文章

@zh

1987年学术文章

@zh-cn

1987年学术文章

@zh-hans

1987年学术文章

@zh-my

1987年学术文章

@zh-sg

1987年學術文章

@yue

1987年學術文章

@zh-hant

name

Acid suppression in duodenal u ...... sing with antisecretory drugs.

@en

Acid suppression in duodenal u ...... sing with antisecretory drugs.

@nl

type

label

Acid suppression in duodenal u ...... sing with antisecretory drugs.

@en

Acid suppression in duodenal u ...... sing with antisecretory drugs.

@nl

prefLabel

Acid suppression in duodenal u ...... sing with antisecretory drugs.

@en

Acid suppression in duodenal u ...... sing with antisecretory drugs.

@nl

P1433

Q43202139-C3046311-F737-4C35-B580-996BADF58AB8

P1476

Q43202139-3AAF4FA1-C5CD-469B-81F2-A300A83704D3

P2093

Q43202139-5FEE5A67-9076-4A31-802A-707E1F2C742D

Q43202139-946994DC-D30A-4460-928A-ABAECA7198B6

Q43202139-BDA7C447-E1E3-46AF-B80A-4FC130D66807

Q43202139-C7512B3E-C470-4471-A7C4-D3E6202E10C8

Q43202139-DF10A6D1-D2C5-4138-B700-08B2DACA7252

P2860

Q43202139-0952AA7C-B86A-4EFD-90C7-DD14A47BFBE5

Q43202139-160A9741-B1E0-4B61-9CA8-A4D6CE4556D5

Q43202139-2D199C1D-985A-401F-9680-464FA192D62A

Q43202139-39AA50FD-5FB7-416A-A0A1-A14B4EEC9BFA

Q43202139-48950981-0371-4667-97FA-9797EB8FC846

Q43202139-50B1E62D-0F4A-4DEB-9F43-D4B965D1803A

Q43202139-61374EBC-0C76-4397-AF5B-0376A8AD70B9

Q43202139-7FA87B7E-A7CF-45B5-8E05-21F3E44B0BFB

Q43202139-812664ED-7409-4E90-8F67-E105D5254FA7

Q43202139-C132D4B4-9262-4B66-B574-E1891C4743E6

P304

Q43202139-28205DC2-ED11-4FB8-B40D-1941AC321970

P31

Q43202139-D85526A5-54D6-4868-9F89-9A50DB22DAB2

P356

Q43202139-D613F990-19FC-427C-AC49-B8026F13218A

P407

Q43202139-D6BAE45C-B532-4573-AF63-C648702A7F59

P433

Q43202139-7465ED96-DDDA-486B-84DC-A892251914D7

P478

Q43202139-A7AEE5AA-14F8-448C-BD72-F6908133E9BD

P577

Q43202139-878F2233-B1C4-418B-9C5A-C26558D8EB09

P5875

Q43202139-68140347-C9AD-4EE4-B0D5-527E7CBECD49

P698

Q43202139-166C7559-2FB3-4012-AA6B-96DA6A640A66

P932

Q43202139-C6AF0DA8-6531-4963-BEBB-78C732C68525

P356

P1433

P1476

Acid suppression in duodenal u ...... sing with antisecretory drugs.

@en

P2093

Burget DW

http://www.w3.org/2001/XMLSchema#string

Howden CW

http://www.w3.org/2001/XMLSchema#string

Hunt RH

http://www.w3.org/2001/XMLSchema#string

Jones DB

http://www.w3.org/2001/XMLSchema#string

Kerr GD

http://www.w3.org/2001/XMLSchema#string

P2860

Controlled trial of maintenance cimetidine treatment in healed duodenal ulcer: short and long-term effects.

Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.

24-hour control of intragastric acidity by cimetidine in duodenal-ulcer patients.

24-hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer during oral administration of cimetidine and atropine

Anticoagulants and myocardial infarction. The problems of pooling, drowning, and floating.

Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.

Effect of daily oral omeprazole on 24 hour intragastric acidity.

Total 24-hour gastric acid secretion in patients with duodenal ulcer. Comparison with normal subjects and effects of cimetidine and parietal cell vagotomy.

Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders.

Comparison of the effects of ranitidine, cimetidine and placebo on the 24 hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer.

P304

1120-1127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.28.9.1120

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

1987-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20264819

http://www.w3.org/2001/XMLSchema#string

P698

2890561

http://www.w3.org/2001/XMLSchema#string

P932

1433241

http://www.w3.org/2001/XMLSchema#string